Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...

Viking Therapeutics Inc (NASDAQ:VKTX) announced that new clinical data from the company’s VK2735 obesity program were ...

你是否在减肥药物的选择上感到困惑？在肥胖症日益成为全球性健康挑战的当下，治疗肥胖的药物市场呈现出前所未有的活力与竞争。在这波健康浪潮中，Viking Therapeutics公司推出的VK2735减肥药吸引了广泛的关注，专家预测这款药物有潜力挑战目前市场上的领航者——诺和诺德的Wegovy和礼来的Zepbound。 肥胖的危害不言而喻，它不仅影响外貌，更与糖尿病、心脏病等多种慢性疾病密切相关。尽管 ...

Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p0.0001). Weight loss ...

Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased ...

Up to 6.8% Placebo-Adjusted Mean weight loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735 ...

Subjects in this cohort were titrated to 80 mg daily doses and subsequently transitioned to a lower exposure regimen (80 mg QoD) from Day 15 – 28. Despite reduction in VK2735 exposure, significant ...